With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there have been many valuable collaborations entering the RNA-targeting field, accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins, and RNA/protein complexes.

Hence, as the go-to meeting for the RNA-targeting small molecule community, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures, delve into innovative preclinical modeling strategies, and identify optimal chemical features for advancing specific, efficacious, and safe small molecules.

Curated in collaboration with large pharma, innovative biotech, and leading academics, the 7th RNA-Targeted Drug Discovery & Development Summit returns with 3 jam-packed days and unrivaled networking opportunities with the key stakeholders to accelerate the discovery of disease-relevant RNA, optimize small molecule design, and uncover novel targets on proteins, enzymes, and RNA/protein complexes to increase the landscape of treatable diseases.

Unite with 100+ RNA Science, Medicinal Chemistry, Structural Biology & Biophysics experts from the likes of AstraZeneca, Sanofi, Novartis, PTC Therapeutics, ReviR Therapeutics, Rgenta Therapeutics, Accent Therapeutics, and more at the most comprehensive and definitive event for the community, the 7th RNA-Targeted Drug Discovery & Development Summit, to accomplish faster and smoother translation of RNA-targeted therapies towards the clinic.

To know more visit: www.rna-drugdiscovery.com